Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Medtronic
Merck
McKesson
Johnson and Johnson

Last Updated: October 1, 2022

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Emtricitabine And Tenofovir Disoproxil Fumarate, and when can generic versions of Emtricitabine And Tenofovir Disoproxil Fumarate launch?

Emtricitabine And Tenofovir Disoproxil Fumarate is a drug marketed by Amneal Pharms Co, Apotex, Aurobindo Pharma Ltd, Cipla, Laurus, Lupin Ltd, Macleods Pharms Ltd, Mylan, Strides Pharma, Teva Pharms Usa, and Zydus Pharms. and is included in eleven NDAs.

The generic ingredient in EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.

Drug patent expirations by year for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Recent Clinical Trials for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le SidaN/A
Prism Health North TexasPhase 3
Merck Sharp & Dohme LLCPhase 3

See all EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE clinical trials

US Patents and Regulatory Information for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms Co EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 209721-001 Aug 22, 2018 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Cipla EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 090958-001 Apr 2, 2021 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Amneal Pharms Co EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 209721-004 Aug 22, 2018 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Medtronic
Boehringer Ingelheim
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.